RO4917838 for sub-optimally controlled schizophrenia symptoms -NN25307

• Research type

  Research Study

• Full title

  Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics followed by a 40-week double-blind, parallel group, placebo-controlled treatment period.

• IRAS ID

  67188

• Contact name

  John Geddes

• Sponsor organisation

  F. Hoffmann-La Roche Ltd

• Eudract number

  2010-020696-23

• ISRCTN Number

  n/a

• Research summary

  This is a Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to determine whether the experimental drug RO4917838 is effective and safe in treating stable patients with sub-optimally controlled symptoms of schizophrenia who are being treated with antipsychotics followed by a 40-week double-blind, parallel-group, placebo-controlled treatment period.

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  10/H0604/94

• Date of REC Opinion

  28 Mar 2011

• REC opinion

  Further Information Favourable Opinion